The incidence of these side effects tends to decrease with continued use and proper dose titration
While extensive data reassure their use, more trials are needed, particularly for populations like children, older adults, and those with severe illness
SeekPeptides has compiled the most thorough breakdown available, pulling from clinical data, pharmacokinetic studies, and thousands of real-world researcher experiences
In one of the clinical trials, SELECT, patients who were treated with semaglutide experienced a 20-28% reduction in major adverse cardiovascular events (MACE) nonfatal myocardial infarction (MI), nonfatal stroke, and cardiovascular death
Aust Prescr 2018;41(3):8285
10.1007/s10103-015-1814-6